• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002393.SZ
Share

Tianjin Lisheng Pharmaceutical Co.,Ltd. Stocks

CN¥ 15.03Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

CN¥ 554.25M

CN¥ 15.03
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, dripping pills, freeze-dried powder injections, and water injections, alongside bulk medicines. The company also provides pharmaceutical intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. Headquartered in Tianjin, China, the firm extends its reach through product exports. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

14.07.2026 23:07

Goldman Sachs set a new record for equity trading revenue. Its stock price soared

14.07.2026 22:06

Apple shares received a rare "sell" recommendation. An analyst identified risks to demand

14.07.2026 21:33

SpaceX will become the internet provider for Frontier flights. Why this matters

14.07.2026 20:52

BofA recommended selling Papa John's stock. What raised analysts' concerns?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026